MetrioPharm AG
MetrioPharm AG announces capital increase
MetrioPharm AG / Capital Increase 04.03.2010 07:45 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. --------------------------------------------------------------------------- MetrioPharm AG announces capital increase +++ Issue of 3,000,000 new shares to strategic investors +++ Gross proceeds of 750,000 Euros +++ Opportunity of for additional patent applications Zurich, 4th March 2010: The governing board and management of MetrioPharm AG (WKN: A0YD9Q; ISIN: CH0107076744) announce the increase of the share capital of the company in cash according to a decision of an extraordinary general meeting of September 30th 2009. The issue of 3,000,000 new registered shares with a nominal value of CHF 0.20 increases the share capital of the company from CHF 8,000,000 by CHF 600,000 to CHF 8,600,000. The preemptive rights of shareholders were excluded. The new shares were subscribed by a group of strategic investors who increased their share in MetrioPharm AG to approximately 7 percent. The shares were issued for a price corresponding to the current market price. MetrioPharm AG will receive gross proceeds of 750,000 Euros. Decisive for the participation of the new investors were the advances with several pipeline products of the company. The MP1000 development pipeline with its lead substance MP1021 as well as the class of oxirane carboxylic acids with its lead substance MP2070/Etomoxir reached several important development milestones earlier than originally projected. In addition, new scientific results open up the possibility for MetrioPharm to file additional patents. This can lead to a substantial increase in the value of the company's drug pipeline. 'Our collaboration with several universities and renowned scientific institutes like the Helmholtz-Center for Infection Research has revealed a number of new therapeutic uses for our MP1000 pipeline and the oxirane carboxylic acids', said Dr. Wolfgang Brysch, president of the governing board of MetrioPharm AG. 'With the proceeds from the capital increase, we want to advance these new results into additional patents and pipeline products.' Based on the statutes of MetrioPharm AG the governing board is authorized to increase the share capital by a maximum of CHF 4,000,000 at any time until the 30th of September 2011. For this capital increase up to 20,000,000 fully liberated registered shares with a nominal value of CHF 0.20 may be issued. About METRIOPHARM AG: MetrioPharm AG is a biotechnology company that specializes in the development and registration of small-molecular drugs which are in an advanced stage of development. Generally positive proof-of-efficacy data in humans exist for the company's pipeline products. Lead substances are the immunomodulator MP1021 for the treatment of severe infectious and inflammatory diseases and MP2070/Etomoxir for the treatment of chronic heart failure. Company Contact: MetrioPharm AG Neuendorfstrasse 20B 16761 Hennigsdorf www.metriopharm.com T. +49 (0) 3302 20 234 02 F. +49 (0) 3302 20 234 99 info@metriopharm.com Investor Relations Contact: GFEI Aktiengesellschaft Hamburger Allee 26-28 60486 Frankfurt am Main www.gfei.de T. +49 (0) 69 743 037 00 F. +49 (0) 69 743 037 22 metriopharm@gfei.de 04.03.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Media archive at www.dgap-medientreff.de and www.dgap.de ---------------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found